Lantern Pharma Announced That The Japan Patent Office Has Issued A Certificate Of Patent For Composition Of Matter Covering Drug Candidate LP-284
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma announced that the Japan Patent Office has issued a certificate of patent for the composition of matter covering their drug candidate LP-284.
June 12, 2024 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma has received a patent from the Japan Patent Office for their drug candidate LP-284, which could enhance their intellectual property portfolio and potentially increase the value of their drug pipeline.
The issuance of a patent for LP-284 in Japan strengthens Lantern Pharma's intellectual property portfolio, potentially increasing the value of their drug pipeline and making the company more attractive to investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100